In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...

Pfizer will price a five-day course of its Covid antiviral drug Paxlovid at $1,390 when the company starts to transition it to the commercial market later this year.

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...

Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance Removes a Significant Uncertainty by Providing Pathway to U.S. Commercialization of Paxlovid on January ...

June 7 (Reuters) - A 15-day course of Pfizer's (PFE.N) COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers.

Pfizer’s Paxlovid is linked to far higher rate of COVID rebound: study Nov. 14, 2023 7:34 AM ET Pfizer Inc. (PFE) Stock By: Dulan Lokuwithana, SA News Editor 109 Comments ...

Pfizer has agreed to supply the U.S. with 10 million courses of Paxlovid for $5.29 billion ($529 per course). On Wednesday, the company also revealed it will supply 2.5 million courses to the U.K ...

The Big Pharma said its COVID-19 oral antiviral, Paxlovid, could soon get a boost from contracts in China and Europe. Pfizer posted (PDF) $25.7 billion in revenues for the first three months of 2022.

Pfizer says that a Phase 2/3 Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) study has found that Paxlovid treatment reduces the risk of hospitalization or death by ...

Pfizer’s application is broadly in line with how Paxlovid is used under its EUA, which the company said covers an estimated 50% to 60% of the population who have at least one risk factor for ...

(Reuters) -Pfizer on Wednesday said it will set the U.S. price for its COVID-19 antiviral treatment Paxlovid at nearly $1,400 per five-day course when it moves to commercial sales after government ...